Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›A casemix classification for those receiving specialist palliative care during their last year of life across England: the C-CHANGE research programme›Workstream 4: testing of the casemix classification

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

A casemix classification for those receiving specialist palliative care during their last year of life across England: the C-CHANGE research programme · Workstream 4: testing of the casemix classification

Workstream 4: testing of the casemix classification

CC BY 4.0 · National Institute for Health and Care Research · approximately 12 min read

This work has also been published in Guo et al.92

Workstream 4 (testing the casemix classification) was planned to meet objective 5: to test this person-centred palliative care casemix classification in terms of its ability to predict resource use in the last year of life, and to better understand transitions between services in order to improve care.

Aim

Our aim was to test the palliative care casemix classification developed in workstream 3 in terms of its ability to predict resource use for patients receiving episodes of specialist palliative care, and to explore the experience of transitions between care settings for those receiving specialist palliative care.

Methods

Design

We designed a multicentre prospective cohort study, following patients during episodes of specialist palliative care, with a qualitative nested component (interviews with a subsample of participants to better understand the experience of transitions between care settings).

Definitions

We defined both an episode of care and the setting of care as in Workstream 3: development of the casemix classification, Definitions.

Population and settings

Patients were recruited from 12 organisations providing specialist palliative care services in England, comprising three hospital advisory services, eight inpatient hospice services and five community-based services (some organisations provided more than one setting of care). Sites were selected for diversity in terms of participant age, ethnic background, service size, proportion of cancer/non-cancer patients and urban–rural balance

Inclusion/exclusion criteria

The inclusion criteria comprised adult patients aged ≥ 18 years who were able to consent and receiving specialist palliative care at any of the participating sites. The exclusion criteria were patients aged < 18 years and those unable to consent.

Data collection and primary outcome

Data were collected from patient participants and clinicians between December 2016 and May 2018. Collected data included demographic and clinical variables, episode start and end dates, casemix variables as required for the casemix classification developed in workstream 3, and data on patient-level and other costs of providing specialist palliative care. All participants received the usual specialist palliative care at that site, including a multidisciplinary team with specialist training delivering holistic care focused on physical and psychological symptom management, social/family support, planning ahead around priorities and preferences, and care into the dying phase including post-death care of the family, where relevant. Details of the measures used are presented in Appendix 1.

Palliative Phase of Illness was assessed daily for people receiving inpatient (hospital or inpatient unit) care and at every contact for those receiving community-based care. Each change in Phase of Illness (or end of episode) triggered the collection of the AKPS, IPOS or PCPSS and Barthel Index score. All staff involved in patient care recorded the time spent delivering care to patient participants at a patient level using the staff activity matrix.

We also collected data from participating sites on the costs of delivering their services, plus patient-level resource use data, as in workstream 3.

A subsample of participants who had experienced at least two transitions between care settings were invited for interview. A purposive sampling approach was used to include participants from a range of age groups, sex, diagnoses, types of transitions in either direction and geographical areas.

Data handling

Quantitative data were collected prospectively at each site, recorded on an electronic database, cleaned and checked. Checked data were transferred to statistical software (Stata SE V.12) for analysis. Qualitative data were recorded, transcribed verbatim and handled using NVivo version 12.

Analysis

For the quantitative data, the casemix classes developed in Workstream 3 were applied to predict costs for episodes of care and this was contrasted with the actual costs captured for each episode of care. For the qualitative data we adopted a similar approach to Pinnock et al.’s qualitative study,93 undertaking a thematic94 and narrative analysis of interviews, exploring how perspectives on transitions evolve over time, with detailed attention to patient and family perspectives on their experience of care in each setting and during transitions, including their experience of interventions that potentially influenced changes in settings of care.

Ethics

The trial registration number is ISRCTN90752212. Written or oral witnessed consent was taken and documented for each participant, and continuing consent was confirmed at follow-up. Ethics approval was received from Bromley REC on 5 September 2016 (REC Reference: 16/LO/1021, IRAS Project ID: 204926).

Quantitative results

Subject characteristics

A total of 309 patients were recruited, providing data on 751 episodes of specialist palliative care. Of these participants, 309 contributed one episode of care, 177 (57%) contributed a second episode of care and 119 (39%) contributed a third episode of care. Only 63 (20%) participants contributed four or more episodes of care. Demographic and clinical characteristics for the 309 participants are reported in Table 5. Just over three-quarters (76%) of participants had cancer, but we were able to recruit one-fifth with a range of different non-cancer conditions.

TABLE 5 Demographic and clinical characteristics for study participants (N = 309)
Characteristicn (%)
Socio-demographic details a
Age
 Mean (SD)66.9 (13.15)
 Median (range)68 (18–96)
 < 65 years117 (37.9)
 ≥ 65 years183 (59.2)
 Missing or prefer not to say9 (2.9)
Sex
 Male134 (43.4)
 Female170 (55.0)
 Missing or prefer not to say5 (1.6)
Ethnicity
 White265 (85.8)
 Black African or Black Caribbean9 (2.9)
 Asian8 (2.6)
 Mixed ethnic background9 (2.9)
 Other11 (3.6)
 Missing or prefer not to say7 (2.2)
Marital status
 Married or partner165 (53.4)
 Separated or divorced43 (13.9)
 Widowed46 (14.9)
 Single46 (14.9)
 Missing or prefer not to say9 (2.9)
Living alone
 Yes107 (34.6)
 No191 (61.8)
 Missing or prefer not to say11 (3.6)
Interpreter neededb
 Yes2 (0.6)
 No302 (97.8)
 Missing5 (1.6)
Primary diagnosis b
Cancer237 (76.7)
 Lip, oral cavity and pharynx1 (0.3)
 Digestive organs55 (17.8)
 Liver and biliary8 (2.6)
 Pancreas10 (3.2)
 Respiratory and intrathoracic46 (14.9)
 Bone, skin and mesothelial11 (3.6)
 Breast28 (9.1)
 Female genital organs16 (5.1)
 Male genital organs including prostate25 (8.1)
 Urinary tract11 (3.6)
 Brain, eye and other central nervous system4 (1.3)
 Unknown primary7 (2.3)
 Lymphoid and haematopoietic15 (4.8)
 Independent multiple sites0 (0.0)
Non-cancer59 (19.1)
 HIV/AIDS1 (0.3)
 Motor neurone disease/ALS11 (3.6)
 Dementia including Alzheimer’s0 (0.0)
 Neurological (excluding MND)8 (2.6)
 Diabetes mellitus0 (0.0)
 Heart failure5 (1.6)
 Stroke, infarction or haemorrhagic0 (0.0)
 Other heart or circulatory0 (0.0)
 Chronic respiratory including COPD28 (9.1)
 Liver failure or chronic liver disease1 (0.3)
 Renal failure1 (0.3)
 All other or multiple non-cancer conditions4 (1.3)
Missing13 (4.2)

Episode characteristics

Details of the episodes of care are reported in Table 6. Seventy-seven episodes of care (10% of all episodes) occurred at sites not participating in the study; although we had endeavoured to include all specialist palliative care sites in each geographical area, inevitably some episodes of care (especially in hospital) were outside of our C-CHANGE sites. Tables 7 and 8 report the duration of episodes of care, by setting and by episode number, respectively. As expected, the median duration of episode was shortest for hospital advisory episodes (10 days) and longest for community episodes (26 days). Note that the absence of the dying Phase of Illness strongly affects these data; those first seen in the dying phase had the shortest length of stay yet are effectively excluded from these data because of the requirement for consent.

TABLE 6 Sequence and setting for all episodes of care (N = 751)
Episode of careSetting, nTotal, n
CommunityHospice inpatientHospital inpatient (advisory)Non-C-CHANGE site: communityaNon-C-CHANGE site: hospice inpatientaNon-C-CHANGE site: hospital inpatient (advisory)aOtherUnknown
1st136641072309
2nd8833131312522177
3rd404319211211119
4th21244210263
5th13124534
6th1082222
7th54211
8th2428
9th325
10th11
11th11
12th11
Total3191951521925655751
TABLE 7 Duration of first, second and third episodes of care, by setting (N = 543)
Duration of episode of care (days)a
CommunityHospice inpatientHospital inpatient (advisory)All settings
Mean (SD)52.67 (67.17)25.31 (29.07)18.38 (29.18)36.48 (53.84)
Median (range)26 (1–365)15.5 (1–168)10 (1–250)17 (1–365)
Missing, n243435b
TABLE 8 Duration of first, second and third episodes of care, by episode (N = 543)
Duration of episode of care (days)a
Episode 1 (n = 307)Episode 2 (n = 134)Episode 3 (n = 102)All (n = 543)
Mean (SD)41.18 (56.73)34.86 (55.74)28.24 (39.76)36.48 (53.84)
Median (range)20 (1–304)15 (1–365)16 (1–250)17 (1–365)
Missing, n233935

Casemix variables

Details of the casemix variables are reported in Table 9. Apart from the dying Phase of Illness, the casemix variables extended across the full range of categories or scores.

TABLE 9 First, second and third episodes of care: settings and casemix variables (n = 543)
Episode characteristicsEpisodes, n (%)a
Setting of care
Hospital advisory139 (25.6)
Inpatient hospice140 (25.8)
Community264 (48.6)
Total543 (100.0)
Palliative Phase of Illness at episode start
Stable193 (35.6)
Unstable195 (35.9)
Deteriorating148 (27.2)
Dying0 (0.0)
Missing7 (1.3)
AKPS score at episode start
Mean (SD) [range]53.5 (14.4) [20–90]
0–50260 (47.9)
60–100271 (49.8)
Missing12 (2.3)
Modified Barthel Index score at episode start
Mean (SD) [range]15.00 (5.2) [1–20]
Missing16 (2.9)
PCPSS at episode start
Pain
 Mean score (SD) [range]1.52 (1.06) [0–3]
 Absent118 (21.8)
 Mild140 (25.7)
 Moderate162 (29.8)
 Severe118 (21.8)
 Missing5 (0.9)
Other physical symptoms
 Mean score (SD) [range]1.03 (0.63) [0–3]
 Absent83 (15.2)
 Mild358 (66.0)
 Moderate80 (14.7)
 Severe12 (2.2)
 Missing10 (1.9)
Psychological symptoms
 Mean score (SD) [range]1.62 (0.88) [0–3]
 Absent49 (9.0)
 Mild186 (34.3)
 Moderate186 (34.3)
 Severe91 (16.7)
 Missing31 (5.7)
Family concerns
 Mean score (SD) [range]2.03 (0.99) [0–3]
 Absent53 (9.8)
 Mild70 (12.9)
 Moderate169 (31.1)
 Severe192 (35.3)
 Missing59 (10.9)

Actual and predicted costs per day

Table 10 presents the actual costs per day, whereas Table 11 compares the predicted class costs with the actual costs per day. The actual cost of inpatient hospice care are consistently higher than the predicted class cost, perhaps because of the 2-year interval between the collection of costs for workstreams 3 and 4 (no uplift was applied) or possibly because of improvements in the application of our costing methodology (the same costing methodology was used in both workstreams, but the teams were more familiar with how to apply it).

TABLE 10 Actual cost per day and length of episodes of care, in Great British pounds and days
Setting of care n %
Hospital advisory13925.6
Inpatient hospice14025.8
Community26448.6
Total543100.0
Mean (SD) Median
Hospital advisory
 Cost per day (£)a50.83 (10.88)51.45 (38.17–57.84)
 Length of episode (days)18.38 (29.18)10 (5.5–15)
Inpatient hospice
 Cost per day (£)a602.02 (257.73)699.61 (536.90–772.66)
 Length of episode (days)25.31 (29.07)15.5 (7.75–24.25)
Community
 Cost per day (£)a34.56 (8.22)32.83 (25.75–40.79)
 Length of episode (days)52.67 (67.17)26 (23–207)
TABLE 11 Actual and predicted cost of episode by casemix class (all costs are per day)
ClassLiving situationPainFunctional statusPalliative phase of illnessFamily distressPhysical symptoms other than painPsychological symptomsSexPredicted class cost (£)Actual cost (£), median
Classes for hospital advisory episodes of care
 ALives alone–––––––8586.44 (75.99–88.94)
 BDoes not live aloneAbsent or mild–Unstable or dying––––7576.87 (70.99–86.33)
 CDoes not live aloneAbsent or mildAKPS ≥ 40%Stable or deteriorating––––6062.12 (53.79–73.61)
 DDoes not live aloneAbsent or mildAKPS ≤ 30%Stable or deteriorating––––7478.22 (70.72–84.51)
 EDoes not live aloneModerate or severe–––––Female9596.55 (89.68–98.44)
 FDoes not live aloneModerate or severe–Stable, deteriorating or dying–––Male7674.47 (69.01–80.37)
 GDoes not live aloneModerate or severe–Unstable–––Male8081.55 (69.87–89.99)
Classes for inpatient hospice episodes of care
 A–Absent, mild or moderate––Absent or mild–––496597.18 (531.80–642.03)
 B–Absent, mild or moderate––Moderate or severe–Absent or mild–648–
 C–Absent, mild or moderate––Moderate or severe–Moderate or severe–9651003.67 (931.49–1088.67)
 D–Severe–Unstable or deteriorating––––657757.07 (710.46–823.62)
 E–Severe–Stable or dying–Absent, mild or moderate––214351.34 (279.67–386.68)
 F–Severe–Stable or dying–Severe––624–
Classes for community episodes of care
 A–––StableAbsent or mild–––2024.80 (21.76–30.56)
 B–––StableModerate or severe–––2425.82 (24.88–28.96)
 C––AKPS ≤ 20%Unstable, deteriorating or dying––––56–
 D––AKPS ≥ 30%Unstable, deteriorating or dying–Absent or mild––2729.57 (27.92–31.33)
 E––AKPS ≥ 30%Unstable, deteriorating or dyingAbsent or mildModerate or severe––2726.90 (25.66–28.92)
 F––AKPS ≥ 30%Unstable, deteriorating or dyingModerate or severeModerate or severe––4040.17 (38.67–41.67)

Qualitative results

A total of 20 interviews with 26 participants were conducted. Participants’ ages ranged from 36 to 91 years (mean 68 years). Of these 20 interviews, 14 were conducted with patients and family caregivers separately and six jointly.

Four main themes and various subthemes were identified from the data analysis.

Theme 1: uncertainty about the new care setting

Lack of information about the new setting of care and patients’ uncertainty regarding their discharge plan predominated in interviews.

Many participants commented on the ‘bad’ timing of a transition in care setting (e.g. emergency admissions during out of hours) and uncertainty around access to care.

Participants highlighted the fact that clear and effective communication is as important as the quality of care delivered; receiving the right information in the right place at the right time helped them to gain a better understanding of their health status and care plan, which reduced their anxiety and worries.

Theme 2: biographical disruption

Sense of identity was considered important but participants felt that transitions often compromised one’s sense of self, which linked to an inevitable loss of control and independence.

Theme 3: importance of continuity of care

Both family and patients praised clinicians who provided continuity and got to know them as individuals. They appreciated not having to retell their stories and recognised the difference in care when staff knew them and their stories.

Participants highlighted the importance of the correct and timely transfer of patient information, medical notes and medication prescriptions; when things were disjointed, patients and their families felt unsafe and that lack of continuity could lead to medical mistakes.

Theme 4: need for emotional and practical support

Family members often act as advocates in the healthcare setting and the majority of participants specified a great need for support from family and friends not only in practical matters, such as arranging transport or coordinating care, but also in the emotional aspect of transitions in care.

← Workstream 3: development of the casemix classificationPatient and public involvement →

Attribution. Fliss EM Murtagh; Ping Guo; Alice Firth; Ka Man Yip; Christina Ramsenthaler; Abdel Douiri et al. (2023). A casemix classification for those receiving specialist palliative care during their last year of life across England: the C-CHANGE research programme. National Institute for Health and Care Research. Copyright © 2023 Murtagh et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK597740. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • Workstream 4: testing of the casemix classification

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support